Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets
AstraZeneca AB
Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
1 trial -
CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED
AstraZeneca AB
Non squamous non-small cell lung cancer (NSCLC)
1 trial -
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet
Janssen-Cilag International N.V.
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
1 trial -
Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Bendatax 6 mg/ ml, TAGRISSO 80 mg film-coated tablets, CISPLATIN, CARBOPLATIN, PEMETREXED, Cisplatin 1mg/ml Concentrate for Solution for Infusion, TAGRISSO 40 mg film-coated tablets, Armisarte 25 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, PACLITAXEL
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, ETOPOSIDE, CISPLATIN, Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil Accord 250 mg capsules, Inflectra 100 mg powder for concentrate for solution for infusion, TAGRISSO 80 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for sol
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
1 trial -
Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Tepotinib
Merck Sharp and Dohme
Lung Cancer
1 trial -
Vizimpro 15 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets
Fondazione Telethon ETS
Advanced or metastatic untreated EGFR mutation positive NSCLC
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets
Fondazione Telethon ETS
Patients with EGFR mutant NSCLC according to TP53 mutational status
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources